Ekam solutions was founded in 2014 by Craig Ferris, professor of Psychology and Pharmaceutical sciences and Praveen Kulkarni, a senior research scientist at Center for Translational Neuroimaging at northeastern University. Craig is a neuroscientist, pioneer of awake animal imaging and among the leader of researchers who have published many articles on small animal imaging. Praveen is computational scientist, has nine years of preclinical imaging experience and is medical image visualization and data analysis expert.

MRI atlases were developed to fill in the need for computationally robust, true to the size and shape brain template to analyze preclinical imaging data. Until now most of the Atlases available in the market are developed from histology slices. Despite advanced techniques, due to inherent process of freezing, the brain shrinks non-linearly and atlases developed from those slices carry over that effect. Registration of these images to MRI/SPECT/CT scans is seldom easy.

Partners

Praveen Kulkarni, PhD, Co-Founder, is a Senior Research Scientist at Center for Translational Neuroimaging (CTNI). Praveen is Computational scientist and has over 10 years of medical image processing and data analysis experience.

Craig Ferris, PhD, Co-Founder, is a professor of Psychology and Pharmaceutical Sciences at Northeastern University and Director of its Center for Translational Neuroimaging (CTNI). Prior to his appointments at Northeastern, he was Professor of Psychiatry and Physiology and Director of the Center for Comparative Neuroimaging at the University of Massachusetts Medical School. Dr. Ferris is well renowned neuroscientist and pioneer of awake animal imaging.

Mark Nedelman, has over 20 years experience in both contract research and pharmaceutical firms. Over a 10 year period, Mark built Primedica Corporation’s Pharmacology and Experimental Surgery program to $18MM in revenue and led the Interventional and Surgical Services Group at Charles River Laboratories to $26MM annual revenue. Earlier in his career, he led preclinical development efforts on several first-in-class drugs at Centocor.